1. Home > 業績について

業績について

原著

2019年

  1. Kawano S, Yamamoto Y. Tuning inflammation: inducing ectodomain shedding of receptor for advanced glycation end-products (RAGE) and formation of soluble RAGE. IMARS Highlights 2019; 14(1): 18-19.
  2. Yamamoto Y, Liang M, Munesue S, Deguchi K, Harashima A, Furuhara K, Yuhi T, Zhong J, Akther S, Goto H, Eguchi Y, Kitao Y, Hori O, Shiraishi Y, Ozaki N, Shimizu Y, Kamide T, Yoshikawa A, Hayashi Y, Nakada M, Lopatina O, Gerasimenko M, Komleva Y, Malinovskaya N, Salmina AB, Asano M, Nishimori K, Shoelson SE, Yamamoto H, Higashida H. Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice. Commun Biol 2019; 2: 76.
  3. Miyoshi A, Koyama S, Sasagawa-Monden M, Kadoya M, Konishi K, Shoji T, Inaba M, Yamamoto Y, Koyama H. JNK and ATF4 as two important platforms for tumor necrosis factor-α-stimulated shedding of receptor for advanced glycation endproducts. FASEB J 2019; 33(3): 3575-3589.
  4. Takamatsu H, Yamamoto K, Tomonobu N, Murata H, Inoue Y, Yamauchi A, Sumardika W, Youyi C, Kinoshita R, Yamamura M, Fujiwara H, Mitsui Y, Araki K, Futami J, Saito K, Iioka H, Ruma MW, Putranto EW, Nishibori M, Kondo E, Yamamoto Y, Toyooka S, Sakaguchi M. Extracellular S100A11 plays a critical role in spread of the fibroblast population in pancreatic cancers. Oncol Res 2019; 27(6): 713-727.
  5. Ichinose W, Cherepanov SM, Shabalova AA, Yokoyama S, Yuhi T, Yamaguchi H, Watanabe A, Yamamoto Y, Okamoto H, Horike S, Terakawa J, Daikoku T, Watanabe M, Mano N, Higashida H, Shuto S. Development of a highly potent analogue and a long-acting analogue of oxytocin for the treatment of social impairment-like behaviors. J Med Chem 2019; 62(7): 3297-3310.
  6. Mitsui Y, Tomonobu N, Watanabe M, Kinoshita R, Sumardika W, Youyi C, Murata H, Yamamoto KI, Sadahira T, Rodrigo AGH, Takamatsu H, Araki K, Yamauchi A, Yamamura M, Fujiwara H, Inoue Y, Futami J, Saito K, Iioka H, Kondo E, Nishibori M, Toyooka S, Yamamoto Y, Nasu Y, Sakaguchi M. Upregulation of mobility in pancreatic cancer cells by secreted S100A11 through activation of surrounding fibroblasts. Oncol Res 2019 in press.
  7. Hosokawa K, Mizumaki H, Elbadry M, Saito C, Espinoza JL, An DTT, Katagiri T, Harashima A, Kikuchi A, Kanai A, Matsui H, Inaba T, Taniwaki M, Yamamoto Y, Nakao S. Clonal hematopoiesis by SLIT1-mutated hematopoietic stem cells due to a breakdown of the autocrine loop involving Slit1 in acquired aplastic anemia. Leukemia 2019 in press.
  8. Roboon J, Hattori T, Ishii H, Takarada-Iemata M, Le TM, Shiraishi Y, Ozaki N, Yamamoto Y, Sugawara A, Okamoto H, Higashida H, Kitao Y, Hori O. Deletion of CD38 suppresses glial activation and neuroinflammation in a mouse model of demyelination. Front Cell Neurosci 2019; 13: 258.
  9. Shimizu Y, Harashima A, Munesue S, Oishi M, Hattori T, Hori O, Kitao Y, Yamamoto H, Leerach N, Nakada M, Yamamoto Y, Hayashi Y. Neuroprotective effects of endogenous secretory receptor for advanced glycation end-products in brain ischemia. Aging Dis 2019 in press.

2018年

  1. Nelissen T, Bamford RA, Tochitani S, Akkus K, Kudzinskas A, Yokoid K, Usui N, Okamoto H, Yamamoto Y, Burbach PH, Matsuzaki H, Oguro-Ando A. CD38 is required for dendritic organisation in visual cortex and hippocampus. Neuroscience 2018; 372: 114-125.
  2. Lam D, Theaker M, Momeni Z, Yamamoto Y, Jagadeeshan S, Campanucci VA. RAGE-dependent potentiation of TRPV1 currents in sensory neurons exposed to high glucose. PLoS ONE 2018; 13(2): e0193312.
  3. Higuchi T, Takeuchi, A, Munesue S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Inatani H, Shimozaki S, Kato T, Aoki Y, Abe K, Taniguchi Y, Aiba H, Murakami H, Harashima A, Yamamoto Y, Tsuchiya H. Anti-tumor effects of a non-steroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression. Cancer Med 2018; 7(5): 1944-1954.
  4. Akther S, Zhong J, Liang M, Cherepanov SM, Lopatina O, Salmina AB, Tsuji C, Tsuji T, Yamamoto Y, Yokoyama S, Higashida H. CD38 in the nucleus accumbens is critical in paternal behavior in mice. Messenger 2018; 6: 81-84.
  5. Tsuji T, Liang M, Lopatina O, Yuhi T, Tsuji C, Zhong J, Akther S, Zhong J, Nishimura T, Amina S, Liu HX, Hashii M, Furuhara K, Yamamoto Y, Yokoyama S, Higashida H. TRPM2, a new player, in cyclic ADP-ribose/CD38-dependent oxytocin release in the hypothalamus. Messenger 2018; 6: 71-75.
  6. Nomura K, Miyashita T, Yamamoto Y, Munesue S, Harashima A, Takayama H, Fushida S, Ohta T. Citrullinated histone H3: early biomarker of neutrophil extracellular traps in septic liver damage. J Surg Res 2018; 234: 132-138.
  7. Kim MJ, Vargas MR, Harlan BA, Killoy KM, Ball L, Comte-Walters S, Gooz M, Yamamoto Y, Beckman JS, Barbeito L, Pehar M. Nitration and glycation turn mature NGF into a toxic factor for motor neurons: a role for p75NTR and RAGE signaling in ALS. Antioxid Redox Signal 2018; 28(18): 1587-1602.
  8. El-Far A, Munesue S, Harashima A, Sato A, Shindo M, Nakajima S, Inada M, Tanaka M, Takeuchi A, Tsuchiya H, Yamamoto H, Shaheen HME, El-Sayed YS, Kawano S, Tanuma S, Yamamoto Y. In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system. Oncology Lett 2018; 15(4): 4627-4634.
  9. Takada S, Miyashita T, Yamamoto Y, Kanou S, Munesue S, Ohbatake Y, Nakanuma S, Okamoto K, Sakai S, Knoshita J, Makino I, Nakamura K, Tajima H, Takamura H, Ninomiya I, Fushida S, Ohta T. Soluble thrombomodulin attenuates endothelial cell damage in hepatic sinusoidal obstruction syndrome. In Vivo 2018; 32(6): 1409-1417.

2017年

  1. Cherepanov S, Yokoyama S, Mizuno A, Ichinose W, Lopatina O, Shabalova A, Salmina A, Yamamoto Y, Okamoto H, Shuto S, Higashida H. Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, plasma and cerebrospinal fluid oxytocin concentrations in mice. Pharmacology Research & Perspectives 2017; 5(1): e00290.
  2. Aikawa T, Matsubara H, Ugaji S, Shirakawa J, Nagai R, Munesue S, Harashima A, Yamamoto Y, Tsuchiya H. Contribution of methylglyoxal to delayed healing of bone injury in diabetes. Mol Med Rep 2017; 16(1): 402-409
  3. Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H, El-Ashry D, Slingerland JM, Lippman ME, Hudson BI. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene 2017; 36(11): 1559-72.
  4. Hattori T, Kaji M, Ishii H, Jureepon R, Takarada-Iemata M, Minh Ta H, Manh Le T, Konno A, Hirai H, Shiraishi Y, Ozaki N, Yamamoto Y, Okamoto H, Yokoyama S, Higashida H, Kitao Y, Hori O. CD38 positively regulates postnatal development of astrocytes cell-autonomously and oligodendrocytes non-cell-autonomously. Glia 2017; 65(6): 974-89.
  5. Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H, Ohta T. Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer. Oncology Rep 2017; 37(6): 3341-3350.
  6. Harashima A, Yamamoto Y. Perception of pathogenic bacteria by pattern recognition receptor RAGE in the frontline. IMARS Highlights 2017; 12(2): 5-7.
  7. Higashida H, Furuhara K, Yamauchi AM, Deguchi K, Harashima A, Munesue S, Lopatina O, Gerasimenko M, Salmina AB, Zhang JS, Kodama H, Kuroda H, Tsuji C, Suto S, Yamamoto H, Yamamoto Y. Intestinal transepithelial permeability of oxytocin into the blood is dependent on the receptor for advanced glycation end products in mice. Sci Rep 2017; 7(1): 7883.
  8. Okamoto H, Takasawa S, Yamamoto Y. From insulin synthesis to secretion: alternative splicing of type 2 ryanodine receptor gene is essential for insulin secretion in pancreatic β cells. Int J Biochem Cell Biol 2017; 91(PtB): 176-183.
  9. Cherepanov SM, Akther S, Nishimura T, Shabalova AA, Mizuno A, Ichinose W, Satoshi Shuto S, Yamamoto Y, Yokoyama S, Higashida H. Effects of three lipidated oxytocin analogs on behavioral deficits in CD38 knockout mice. Brain Sci 2017; 7(10): E132.
  10. Munesue S, Yamamoto Y. Targeting RAGE: a viable strategy for cancer prevention and treatment? IMARS Highlights 2017; 12(6): 5-6.

2016年

  1. Iwamura M, Yamamoto Y, Kitayama Y, Higuchi K, Fujimura T, Hase T, Yamamoto H. Epidermal expression of receptor for advanced glycation end-products (RAGE) is related to inflammation and apoptosis in human skin. Exp Dermatology 2016; 25(3): 235-7.
  2. Ota C, Ishizawa K, Yamada M, Tando Y, Mei H, Takahashi T, Yamamoto Y, Yamamoto H, Kubo H. The receptor for advanced glycation end-products is associated with apoptosis of alveolar epithelial cells in hyperoxia exposure in vitro and in vivo. Respiratory Invest 2016; 54(2): 98-108.
  3. Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H, Ohta T. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer 2016; 19(4): 1052-65.
  4. Ichiki T, Koga T, Okuno T, Saeki K, Yamamoto Y, Yamamoto H, Sakaguchi M, Yokomizo T. Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products, RAGE. FASEB J 2016; 30(5): 1811-22.
  5. Lee BC, Kim MS, Pae M, Yamamoto Y, Eberlé D, Shimada T, Kamei N, Park HS, Sasorith S, Woo JR, You J, Mosher W, Brady HJM, Shoelson SE, Lee J. Adipose natural killer cells regulate adipose tissue macrophages to promote insulin resistance in obesity. Cell Metab 2016; 23(4): 685-98.
  6. Zhong J, Amina S, Liang M, Akther S, Yuhi T, Nishimura T, Higashida C, Tsuji T, Liu HX, Hashii M, Furuhara K, Yokoyama S, Yamamoto Y, Okamoto H, Zhao YJ, Lee HC, Tominaga M, OLopatina O, Higashida H. Cyclic ADP-ribose and heat regulate oxytocin release via CD38 and TRPM2 in the hypothalamus during social or psychological stress in mice. Front Neurosci 2016; 10: 304.
  7. Ta H, Le T, Ishii H, Takarada-Iemata M, Hattori, T, Hashida K, Yamamoto Y, Mori K, Takahashi R, Kitao Y, Hori O. Atf6α deficiency suppresses microglial activation and ameliorates pathology of experimental autoimmune encephalomyelitis. J Neurochem 2016; 139(6): 1124-37.
  8. Takeuchi A, Yamamoto N, Shirai T, Hayashi K, Miwa S, Munesue S, Yamamoto Y, Tsuchiya H. Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. BMC Cancer 2016; 16: 442.
  9. Miyashita M, Watanabe T, Ichikawa T, Toriumi K, Horiuchi Y, Kobori A, Kushima I, Hashimoto R, Fukumoto M, Koike S, Ujike H, Arinami T, Tatebayashi Y, Kasai K, Takeda M, Ozaki N, Okazaki Y, Yoshikawa T, Amano N, Washizuka S, Yamamoto H, Miyata T, Itokawa M, Yamamoto Y, Arai M. The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia. Biochem Biophys Res Commun 2016; 479(3): 447-52.
  10. Abouzed TK, Munesue S, Harashima A, Masuo Y, Kato Y, Kahilo K, Yamamoto H, Yamamoto Y. Preventive effect of salicylate and pyridoxamine on diabetic nephropathy. J Diabetes Res 2016; 2016:1786789.

2015年

  1. Chandna AR, Baskaran MN, Chang C, Pennington PR, Mousseau DD, Yamamoto Y, Campanucci VA. RAGE mediates the interactivation of nAChRs in sympathetic neurons during high glucose conditions. Eur J Neurosci 2015; 41(3):341-51.
  2. Inaba Y, Furutani T, Kimura K, Watanabe H, Haga S, Kido Y, Yamamoto Y, Harada K, Kaneko S, Oyadomari S, Ozaki M, Kasuga M, Inoue H. Gadd34 regulates liver regeneration in hepatic steatosis. Hepatology 2015; 61(4): 1343-56.
  3. Waseda K, Miyahara N, Taniguchi A, Kurimoto E, Ikeda G, Koga H, Fujii U, Yamamoto Y, Gelfand EW, Yamamoto H, Tanimoto M, Kanehiro A. Emphysema requires the receptor for advanced glycation end products triggering on structural cells. Am J Respir Cell Mol Biol 2015; 52(4): 482-491.
  4. Taniguchi A, Miyahara N, Waseda K, Kurimoto E, Fuji U, Tanimoto Y, Kataoka M, Yamamoto, Y, Gelfand E, Tanimoto M, Yamamoto H, Kanehiro A. Contrasting Roles for the Receptor for Advanced Glycation End-Products on Structural Cells in Allergic Airway Inflammation versus Airway Hyperresponsiveness. Am J Physiol Lung Cell Mol Physiol 2015; 309(8): L789-800.

2014年

  1. Toda M, D'Alessandro-Gabazza CN, Takagi T, Chelakkot-Govindalayathila AL, Taguchi O, Roeen Z, Munesue S, Yamamoto Y, Yamamoto H, Gabazza EC, Morser J. Thrombomodulin modulates dendritic cells via both antagonism of high mobility group protein B1 and an independent mechanism. Allergology Int 2014; 63(1):57-66.
  2. Kuretani A, Kawamura R, Munesue S, Yamamoto Y, Honda J, Yamamoto H. Maltitol endows foods with lower 3-deoxyglucosone content and less RAGE agonism as a sweetener against sucrose. Glycative Stress Res 2014; 1(2):25-31.
  3. Okuma Y, Liu K, Wake H, Liu R, Nishimura Y, Hui Z, Teshigawara K, Haruma J, Yamamoto Y, Yamamoto H, Date I, Takahashi HK, Mori S, Nishibori M. Glycyrrhizin inhibits traumatic brain injury in rats by reducing HMGB1-RAGE interaction. Neuropharmacology 2014; 85:18-26.
  4. Motoyoshi S, Yamamoto Y, Munesue S, Igawa H, Harashima A, Saito H, Han H, Watanabe T, Sato H, Yamamoto H. cAMP ameliorates inflammation in macrophages by modulation of receptor for advanced glycation end-products. Biochem J 2014; 463(1): 75-82.
  5. Anisuzzaman, Hatta T, Miyoshi T, Mtsubayashi M, Islam MK, Alim MA, Anas MA, Hasan MM, Matsumoto Y, Yamamoto Y, Yamamoto H, Fujisaki K, Tsuji N. Longistatin secreted with tick saliva blocks RAGE. J Clin Invest 2014; 124(10):4429-44.
  6. Chen X, Zhang L, Zhang IY, Liang J, Wang H, Ouyang M, Wu S, da Fonseca ACC, Weng L, Yamamoto Y, Yamamoto H, Natarajan R, Badie B. Expression of RAGE by tumor macrophages promotes angiogenesis in gliomas. Cancer Res 2014; 74(24):7285-97.
  7. Sakai S, Tajima H, Miyashita T, Nakanuma SI, Makino I, Hayashi H, Nakagawara H, Kitagawa H, Fushida S, Fujimura T, Saito H, Munesue S, Yamamoto Y, Ohta T. Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury. Dig Dis Sci 2014; 59(4):787-94.
  8. Harada K, Kakuda Y, Sato Y, Ikeda H, Shimoda S, Yamamoto Y, Inoue H, Ohta H, Kasashima S, Kawashima A, Nakanuma Y. Alteration of energy metabolism in the pathogenesis of bile duct lesions in primary biliary cirrhosis. J Clin Pathol 2014; 67(5):396-402.
  9. Ullah MA, Loh Z, Gan WJ, Zhang V, Yang H, Li JH, Yamamoto Y, Schmidt AM, Armour CL, Hughes JM, Phipps S, Sukkar MB. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. J Allergy Clin Immunol 2014; 134(2): 440-50.

2013年

  1. Myat TTW, Yamamoto Y, Munesue S, Han D, Harada S, Yamamoto H. Validated liquid culture monitoring system for lifespan extension of Caenorhabditis elegans through genetic and dietary manipulations. Aging Dis 2013; 4(4):178-85.
  2. Akther S, Korshnova N, Zhong J, Liang M, Cherepanov SM, Lopatina O, Komleva YK, Salmina AB, Nishimura T, Fakhrul AAKM, Hirai H, Kato I, Yamamoto Y, Takasawa S, Okamoto H, Higashida H. CD38 in the nucleus accumbens and oxytocin are related to paternal behavior in mice. Mol Brain 2013; 6:41.
  3. Kim MS, Yamamoto Y, Kim K, Kamei N, Shimada T, Liu L, Moore K, Woo JR, Shoelson SE, Lee J. Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone. PLoS ONE 2013; 8(12):e82847.
  4. Takeuchi A, Yamamoto Y, Munesue S, Harashima A, Shimizu K, Yonekura H, Yamamoto H, Tsuchiya H. Low molecular weight heparin inhibits RAGE-dependent human fibrosarcoma cell growth and metastasis. Cancer Sci 2013; 104(6):740-9.
  5. Takahashi HK, Sadamori H, Liu K, Wake H, Mori S, Yoshino T, Yamamoto Y, Yamamoto H, Nishibori M. Role of cell-cell interactions in HMGB1 cytokine activity in human PBMCs and mouse splenocytes. Eur J Pharmacol 2013; 701(1-3):194-202.
  6. Monden M, Koyama H, Otsuka Y, Morioka T, Mori K, Shoji T, Mima Y, Motoyama K, Fukumoto S, Shioi A, Emoto M, Yamamoto Y, Yamamoto H, Nishizawa Y, Kurajoh M, Yamamoto T, Inaba M. Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of toll-like receptor 2. Diabetes 2013; 62(2):478-89.
  7. Han D, Yamamoto Y, Munesue S, Motoyoshi S, Saito H, Myat TTW, Watanabe T, Tsuneyama K, Yamamoto H. Induction of RAGE by insufficient leptin action triggers pancreatic β-cell failure in type 2 diabetes. Genes Cells 2013; 18(4):302-14.
  8. Munesue S, Yamamoto Y, Urushihara R, Inomata K, Saito H, Motoyoshi S, Watanabe T, Yonekura H, Yamamoto H. Low-molecular weight fractions of Japanese soy sauce act as a RAGE antagonist via inhibition of RAGE trafficking to lipid rafts. Food Funct 2013; 4(12):1835-42.
  9. Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, Ahn J, Gutman D, Barber GN. STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell 2013; 50(1):5-15.

2012年

  1. Kitade H, Sawamoto H, Nagashimada M, Inoue H, Yamamoto Y, Sai Y, Takamura T, Yamamoto H, Miyamoto K, Ginsberg HN, Mukaida N, Kaneko S, Ota T. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 2012; 61(7):1680-90.
  2. Saito H, Yamamoto Y, Yamamoto H. Diabetes alters the subsets of mouse endothelial progenitor cells that reside in blood, bone marrow and spleen. Am J Physiol Cell Physiol 2012; 302(6):C892-901.
  3. Sugihara T, Munesue S, Yamamoto Y, Sakurai S, Akhter N, Kitamura Y, Shiba K, Watanabe T, Yonekura H, Hayashi Y, Hamada J, Yamamoto H. Endogenous secretory receptor for advanced glycation end-products inhibits amyloid-β1-42 uptake into mouse brain. J Alzheimer’s Dis 2012; 28(3):709-20.
  4. Kamide T, Kitao Y, Takeichi T, Okada A, Mohri H, Schmidt AM, Kawano T, Munesue S, Yamamoto Y, Yamamoto H, Hamada J, Hori O. RAGE mediates vascular injury and delayed neuronal death after global cerebral ischemia. Neurochem Int 2012; 60(3):220-8.
  5. Okuma Y, Liu K, Wake H, Zhang J, Maruo T, Date I, Yoshino T, Ohtsuka A, Otani N, Tomura S, Shima K, Yamamoto Y, Yamamoto H, Takahashi HK, Mori S, Nishibori M. Anti-HMGB1 monoclonal antibody ameliorates fluid percussion-induced brain injury in rats through protection of BBB and inhibition of inflammatory responses. Ann Neurol 2012; 72(3):373-84.

2011年

  1. Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Han D, Watanabe T, Asano M, Takasawa S, Okamoto H, Shimura S, Karasawa T, Yonekura H, Yamamoto H. Septic shock is associated with receptor for advanced glycation endproducts (RAGE) ligation of LPS. J Immunol 2011; 186(5):3248-57.
  2. Takagi T, Taguchi O, D’Alessandro-Gabazza CN, Toda M, Kobayashi T, Boveda Ruiz, Gil Bernabe P, Aoki S, Chiba F, Yano Y, Conway EM, Munesue S, Yamamoto Y, Yamamoto H, Suzuki K, Takei Y, Morser Y, Esteban C.Gabazza. Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med 2011; 183(1):31-42.
  3. He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahashi T, Yamada M, Yamaya M, Yamamoto Y, Yamamoto H. RAGE binds phosphatidylserine and mediates clearance of apoptotic cells. EMBO Rep 2011; 12(4):358-64.
  4. Riazy M, Chen JH, Yamamoto Y, Yamamoto H, Duronio V, Steinbrecher UP. OxLDL mediated survival of macrophages does not require LDL internalization or signaling by major pattern recognition receptors. Biochem Cell Biol 2011; 89(4):387-95.

2010年

  1. Hamada Y, Kitazawa S, Kitazawa R, Kono K, Goto S, Komaba H, Fujii H, Yamamoto Y, Yamamoto H, Usami M, Fukagawa M. The effects of receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic condition. Endocrine 2010; 38(3):369-76.
  2. Ohe K, Watanabe T, Harada S, Munesue S, Yamamoto Y, Yonekura H, Yamamoto H. Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein (hnRNP) H. J Biochem 2010; 147(5):651-9.
  3. Ilchmann A, Burgdorf S, Waibler Z, Nagai R, Wellner A, Yamamoto Y, Yamamoto H, Scheurer S, Henle T, Kurts C, Kalinke U, Vieths S, Toda M. Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: the role of macrophage scavenger receptor class A type I and II. J Allergy Clin Immunol 2010; 125(1):175-83.
  4. Li J, Qu X, Yao J, Caruana G, Ricardo SD, Yamamoto Y, Yamamoto H, Bertram JF. Blockade of endothelial-mesenchymal-transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010; 59(10):2612-24.
  5. Harashima A, Guettouche T, Barber GN. Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase PKR constitutes a novel mechanism of translational regulation and cellular defense. Genes Dev 2010; 24(23):2640-53.

2009年以前

  1. Yamagishi S, Hsu CC, Taniguchi M, Harada S, Yamamoto Y, Ohsawa K, Kobayashi K, YamamotoH. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 1995; 213:681-7.
  2. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun 1996; 222:700-3.
  3. Yamagishi S, Yamamoto Y, Harada S, Hsu CC, Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett 1996; 384:103-6.
  4. Nagai Y, Ohsawa K, Ohta M, Hisada A, Yamashita H, Yoshizawa M, Yamamoto Y, Takamura T, Kobayashi K. Inhibitory effect of cyclosporin A on prolactin synthesis in GH3 cells. Tohoku J Exp Med 1996; 180:337-46.
  5. Yamamoto Y, Yamagishi S, Noto Y, Taniguchi M, Nagai Y, Ohsawa K, Kida H, Kobayashi K. The first case of insulin-dependent diabetes mellitus with prominent spurious hyperglucagonemia due to interference of immunoglobulin G in glucagon radioimmunoassay (OAL-123) system. Horm Res 1996; 45:295-9.
  6. Yamamoto Y, Noto Y, Saito M, Ichizen H, Kida H. Spinal cord compression by heterotopic ossification associated with Pseudohypoparathyroidism. J Int Med Res 1997; 25:364-8.
  7. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation endproducts-driven angiogenesis in vitro: Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997; 272:8723-30.
  8. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41:1435-41.
  9. Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, Nomura M, Abedin Md J, Unoki H, Yamamoto Y, Yamamoto H. Placenta growth factor and vascular endothelial growth factor B and C expressions in microvascular endothelial cells and pericytes: implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem 1999; 274(49):35172-8.
  10. Yamagishi S, Kawakami T, Fujimori H, Yonekura H, Tanaka N, Yamamoto Y, Urayama H, Watanabe Y, Yamamoto H. Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. Microvasc Res 1999; 57:329-39.
  11. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, Yamamoto H. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 1999; 79:501-9.
  12. Kato I, Yamamoto Y, Fujimura M, Noguchi N, Takasawa S, Okamoto H. CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion. J Biol Chem 1999; 274(4):1869-72.
  13. Abedin MdJ, Yonekura H, Migita H, Karasawa J, Yamamoto Y, Yamamoto H. Molecular heterogeneity of the receptor for advanced glycation endproducts. J Biochem Mol Biol Biophys 2000; 4:373-81.
  14. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation endproducts is induced by the glycation products themselves and TNF-α through NF-KB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275(33):25781-90.
  15. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108(2):261-8.
  16. Nakajima M, Kwon JT, Tanaka N, Zenda T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T. Relationship between interindividual differences in nicotine metabolism and CYR2A6 genetic polymorphism in humans. Clin Pharmcol Ther 2001; 68:72-8.
  17. Petrova RG, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 2002; 34(10):1425-31.
  18. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Petrova RG, Abedin MdJ, Li H, Yasui K, Takasawa S, Okamoto H, Yamamoto H. Novel splice variants of the receptor for advanced glycation endproducts (RAGE) expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370:1097-109.
  19. Miura J, Uchigata Y, Yamamoto Y, Takeuchi M, Sakurai S, Watanabe T, Yonekura H, Yamagishi S, Makita Z, Sato A, Omori Y, Yamamoto H, Iwamoto Y. AGE downregulation of monocyte expression of RAGE mRNA and its association with diabetic complications in type 1 diabetes. J Diabetes Complication 2004; 18:53-60.
  20. Ohashi S, Abe H, Takahashi T, Yamamoto Y, Takeuchi M, Arai H, Nagata K, Kita T, Okamoto H, Yamamoto H, Doi T. Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy. J Biol Chem 2004; 279:19816-23.
  21. Li H, Yonekura H, Kim CH, Sakurai S, Yamamoto Y, Takiya T, Futo S, Watanabe T, Yamamoto H. Possible participation of pICln in the regulation of angiogenesis through alternative splicing of VEGF receptor mRNAs. Endothelium 2004; 11(5-6):293-300.
  22. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y*. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005; 18(10):1385-96. (*corresponding)
  23. Abeyama K, Stern MD, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Murayama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115(5):1267-74.
  24. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y. Plasma level of endogenous secretory receptor for advanced glycation endproducts (esRAGE) is associated with components of the metabolic syndrome and atherosclerotic arterial wall thickness. Arterioscler Thromb Vasc Biol 2005; 25(12):2587-93.
  25. Harashima A, Yamamoto Y, Cheng C, Tsuneyama K, Myint KM, Takeuchi A, Yoshimura K, Li H, Watanabe T, Takasawa S, Okamoto H, Yonekura H, Yamamoto H. Identification of mouse ortholog of endogenous secretory receptor for advanced glycation endproducts: structure, function and expression. Biochem J 2006; 396(1):109-15.
  26. Inagi R, Yamamoto Y, Nangaku M, Usuda M, Okamato H, Kurokawa K, van Ypersele de Strihou C, Yamamoto H, Miyata T. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in the RAGE/iNOS transgenic mice. Diabetes 2006; 55:356-66.
  27. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata H, Hui L, Miura J, Osawa M, Uchigata Y, Iwamoto Y, Watanabe T, Yonekura H, Yamamoto H. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006; 73:158-65.
  28. Myint KM, Yamamoto Y*, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low molecular weight heparin. Diabetes 2006; 55(9):2510-22. (*equally contributed)
  29. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Shioi A, Yamamoto Y, Yamamoto H, Nishizawa Y. Receptor for advanced glycation endproducts is involved in impaired angiogenic response in diabetes. Diabetes 2006; 55(8):2245-55.
  30. Nakajima M, Itoh M, Yamanaka H, Fukami T, Tokudome S, Yamamoto Y, Yamamoto H, Yokoi T. Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. J Clin Pharmacol 2006; 46(3):337-44.
  31. Kobayashi S, Kubo H, Suzuki T, Ishizawa K, Yamada M, He M, Yamamoto Y, Yamamoto H, Sasano H, Sasaki H, Suzuki S. Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. Am J Respir Crit Care Med 2007; 175(2):184-9.
  32. Miura J, Yamamoto Y, Osawa M, Watanabe T, Yonekura H, Uchigata Y, Yamamoto H, Iwamoto Y. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 2007; 27(1):253-4.
  33. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TCB, Moore J, Yamamoto Y, Yamamoto H, Adamis AP. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthal Vis Sci 2007; 48(2):858-65.
  34. Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi A, Takeuchi M, Yamamoto H. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 2007; 1:s30-40.
  35. Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K, Yamamoto H, Tsuchiya H. Endogenous secretory receptor for advanced glycation end-products as a novel prognostic marker in chondrosarcoma. Cancer 2007; 109(12):2532-40.
  36. He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, Yamaya M. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293(6):L1427-36.
  37. Osawa M, Yamamoto Y*, Sakurai S, Watanabe T, Yonekura H, Uchigata Y, Iwamoto Y, Yamamoto H. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochem Biophy Acta 2007; 1770(10):1468-74. (*corresponding)
  38. Nozaki I, Watanabe T, Kawaguchi M, Akatsu H, Tsuneyama K, Yamamoto Y, Ohe K, Yonekura H, Yamada M, Yamamoto H. Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer’s disease brains. Arch Histol Cytol 2007; 70(5):279-90.
  39. Sakatani S, Seto-Ohshima A, Shinohara Y, Yamamoto Y, Yamamoto H, Itohara S, Hirose H. Neural activity dependent release of S100B from astrocytes enhances kainite-induced gamma oscillations in vivo. J Neurosci 2008; 28(43):10928-36.
  40. Matsumoto S, Yoshida T, Murata H, Harada S, Fujita N, Nakamura S, Yamamoto Y, Watanabe T, Yonekura H, Yamamoto H, Ohkubo T, Kobayashi Y. The solution structure of variable-type domain of receptor for advanced glycation endproducts: a new insight into AGE-RAGE interaction. Biochemistry 2008; 47(47):12299-311.
  41. Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 2009; 82(2):371-81.
  42. Sakatani S, Yamada K, Homma C, Munesue S, Yamamoto Y, Yamamoto H, Hirase H. Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice. PLoS ONE 2009; 4(12):e8309.
  43. Mi QS, Yan SL, Wang ZZ, Ding KH, Li C, Wang L, Zhou L, Yamamoto Y, Yamamoto H, Okamoto H, Isales C. Spontaneous bone loss in RIP-iNOS transgenic mouse: A mouse model for diabetes- mediated osteopenia/osteoporosis. Cell Cycle 2009; 8(24):4179-81.

著書

  1. べインズ・ドミニチャク 生化学「谷口直之、岩井一宏、藤井順逸、本家孝一監訳」 山本靖彦 「第43章老化」 pp.634-645 2018年 エルゼビアジャパン
  2. 基礎生化学-健康・疾患とのつながり-「永井竜児、大島寛史編」山本靖彦「14章血液の機能」pp.182-9 2013年 アイケーコーポレーション
  3. Diabetic Nephropathy (Ed Chan JSD) Kamal T, Yamamoto Y, Yamamoto H. Significance of AGE and RAGE in diabetic nephropathy. pp. 97-108, INTECH 2012
  4. 血管生物学医学事典「日本血管生物医学会編」山本靖彦,山本博「第4章AGE受容体」pp.284-5 2011年 朝倉書店
  5. 糖化による疾患と抗糖化食品・素材「米井嘉一編」山本靖彦,山本博「AGE受容体RAGEの役割」pp.114-21 2010年 シーエムシー出版
  6. 医学書院医学大辞典「伊藤正男,井村裕夫,高久史麿編」山本靖彦「補足遺伝子、ホモ接合性」pp.2292, pp.2302 2003年 医学書院
  7. 医学のための基礎分子細胞生物学(改訂3版)「平賀紘一,山本博,伊達孝保,宮本薫編」山本靖彦「コレステロールとリポタンパク質」pp.54-5 2003年 南山堂

総説

  1. 金沢大学十全医学会雑誌 山本靖彦「オキシトシンによる母親の養育行動にはパターン認識受容体RAGEが関わる」第128巻 第1号pp.12-13 2019年 金沢大学十全医学会
  2. 分子神経医学 東田陽博、山本靖彦「パターン認識受容体RAGEはオキシトシンと結合し脳内への輸送を行う」2019年10月号
  3. 糖尿病合併症 山本靖彦「グリケーションと糖尿病合併症」 2019年in press 日本糖尿病合併症学会
  4. Thrombosis Medicine 河野修平、棟居聖一、山本靖彦 「HMGB1-RAGE系を標的とした抗腫瘍効果について」 8(2) pp.30-35 2018年 先端医学社
  5. 循環制御 山本靖彦 「グリケーションによる糖化ストレスとその受容体による血管障害機構」 38(1) pp.11-12 2017年 日本循環制御医学会
  6. 月刊糖尿病学2017年 原島愛,棟居聖一,山本靖彦 「AGE-RAGE系と糖尿病」pp.70-76 2017年 医学出版
  7. 日本臨床 原島愛,棟居聖一,山本靖彦「新時代の臨床糖尿病学(下)X. 糖尿病合併症―発症・進展の分子機序― AGE-RAGE系」74(2) pp.49-52 2016年 日本臨床社
  8. BIO Clinica山本靖彦「BIOLOGY TOPICS パターン認識受容体RAGEの切断により糖尿病合併症を制御する」31(3) 2016年 北隆館
  9. BIO Clinica山本靖彦「BIOLOGY TOPICS 糖尿病合併症発症の分子機構:避けられない糖化反応とその終末糖化産物受容体RAGE」31(6) pp.100-103 2016年 北隆館
  10. グルコサミン研究 山本靖彦「糖化反応と細胞応答さらにその制御系―生理的役割と病態形成への関わり」11 pp.66-71 2015年 グルコサミン研究会
  11. 最新医学 糖尿病と合併症 山本靖彦「メイラード反応と終末糖化産物(AGEs)」70(7) pp.40-44 2015年 最新医学社
  12. 日本食生活学会誌 山本靖彦,棟居聖一「糖化制御と生活習慣病の予防」25(4) pp.237-240 2015年 日本食生活学会
  13. Yamamoto Y, Yamamoto H. Enzymatic and non-enzymatic post-translational modifications linking diabetes and heart disease. J Diabetes Invest 2015; 6(1):16-7.
  14. 金沢大学十全医学会雑誌 山本靖彦「パターン認識受容体RAGEの生理的役割と病態への関与」123(1) pp.8-12 2014年 金沢大学十全医学会
  15. 日本薬理学会雑誌 山本靖彦,山本博「パターン認識受容体RAGEによる病態とそれに対する創薬を考える」143(1) pp.10-3 2014年 日本薬理学会
  16. アンチ・エイジング医学 特集今後期待される新規バイオマーカー 山本靖彦, 後藤久典, 山本博「加齢疾患におけるAGEs-RAGE系と関連バイオマーカー」10(1) pp.45-50 2014年 日本抗加齢医学会
  17. 医学のあゆみ 原島愛,山本靖彦,山本博「RAGEと敗血症性ショック」244(8) pp.681-4 2013年 医歯薬出版
  18. 糖尿病の分子標的と治療薬辞典 7章合併症 山本靖彦 pp.216-26 2013年 羊土社
  19. Yamamoto Y, Yamamoto H. RAGE-mediated inflammation, type 2 diabetes and diabetic vascular complication. Front Endocrinol 2013; 4:105.
  20. 糖尿病合併症 山本靖彦,山本博「Glucotoxicityと細小血管症」27(1) pp.76-8 2013年 日本糖尿病合併症学会
  21. Myat TTW, Yamamoto Y, Munesue S, Saito H, Han D, Motoyoshi S, Kamal T, Ohara T, Watanabe T, Yamamoto H. Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res 2012; 2012:894605.
  22. 糖尿病イラストレイテッド 山本靖彦,山本博「細小血管症発症の分子機構(総論)」pp.210-3 2012年 南江堂
  23. シリーズ ヴィジュアル糖尿病臨床のすべて 糖尿病腎症のすべて 山本靖彦,山本博「RAGE、AGEs」pp.21-5 2012年 中山書店
  24. アンチ・エイジング医学 特集老化を促進する危険因子としての糖化ストレス 山本靖彦「AGEs受容体」8(1) pp.25-8 2012年 日本抗加齢医学会
  25. BIO Clinica 12 月臨時増刊号 糖尿病合併症と治療薬 杉浦英恵,山本靖彦,山本博pp.18-23 2012年 北隆館
  26. メディカル・サイエンス・ダイジェスト(MSD)「糖尿病合併症の成因」齋藤英仁,山本靖彦,山本博 pp.338-41 2012年 ニューサイエンス社
  27. Yamamoto Y, Yamamoto H. Controlling RAGE to conquer diabetic vascular complications. J Diabetes Invest 2012; 3(2):107-14.
  28. Nagai R, Jinno M, Ichihashi M, Koyama H, Yamamoto Y, Yonei Y. Advanced glycation end products and their receptors as risk factors for aging. Anti-aging Med 2012; 9(4):108-13.
  29. Yamamoto Y, Yamamoto H. Interaction of receptor for advanced glycation end products with advanced oxidation protein products induces podocyte injury. Kidney Int 2012; 82(7):733-5.
  30. Yamamoto Y, Yamamoto H. RAGE-mediated inflammation and diabetic vascular complications. J Diabetes Invest 2011; 2(3):155-7.
  31. Nagai R, Mori T, Yamamoto Y, Kaji Y, Yonei Y. Significance of advanced glycation endproducts (AGEs) in aging-related disease. Anti-aging Med 2010; 7(10):112-9.
  32. 日本臨床 増刊号 山本靖彦,山本博「AGEおよびRAGEの役割」pp.39-44 2010年 日本臨床社
  33. 糖尿病合併症 山本靖彦「遺伝子改変技術を用いた糖尿病合併症の発症機構とモデル動物開発に関する研究」pp.138-43 2009年 日本糖尿病合併症学会
  34. Yamamoto H, Watanabe T, Yamamoto Y, Yonekura H, Munesue S, Harashima A, Ohe K, Hossain S, Saito H, Murakami N. RAGE in diabetic nephropathy. Curr Mol Med 2007; 7(8):752-7.
  35. Yamamoto Y, Miura J, Sakurai S, Watanabe T, Uchigata Y, Iwamoto Y, Koyama H, Yamamoto H. Assaying soluble forms of receptor for advanced glycation endproducts. Arterioscler Thromb Vasc Biol 2007; 27:33-4.
  36. カラー版糖尿病学 基礎と臨床 山本靖彦,山本博「合併症におけるRAGE」pp.1158-60 2007年 西村書店
  37. 内分泌・糖尿病科 山本靖彦,山本博「糖尿病腎症におけるRAGEの役割」 pp.545-51 2007年 科学評論社
  38. 糖尿病カレントライブラリー 山本靖彦,原島愛,米倉秀人,渡邉琢夫,山本博「糖尿病性腎症とRAGE」pp.112-5 2006年 文光堂
  39. 糖尿病学の進歩 第40集 山本靖彦,米倉秀人,渡邉琢夫,山本博「グリケーションと糖尿病腎症」pp.250-3 2006年 診断と治療社
  40. Myint KM, Yamamoto Y, Sakurai S, Harashima A, Watanabe T, Li H, Takeuchi A, Yoshimura K, Yonekura H, Yamamoto H. Blockage of diabetic vascular injury by controlling of AGE-RAGE system. Current Drug Targets 2005; 6(4):447-52.
  41. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto, H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 2005; 97(3):305-11.
  42. Yamamoto Y, Doi T, Kato I, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Myint KM, Harashima A, Takeuchi M, Takasawa S, Okamoto H, Hashimoto N, Asano M, Yamamoto H. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann NY Acad Sci 2005; 1043:562-6.
  43. 内分泌・糖尿病科 特集7 山本靖彦,米倉秀人,櫻井繁,渡邉琢夫,山本博「糖尿病腎症の発症と進展 糖尿病腎症におけるAGE-RAGE相互作用」pp.243-50 2005年 科学評論社
  44. 日本臨床 63巻 増刊号 原島愛,山本靖彦,山本博「AGE-RAGE系」pp.62-6 2005年 日本臨牀社
  45. Yamamoto Y, Yonekura H, Sakurai S, Tanaka N, Li H, Myint KM, Kim CH, Harashima A, Osawa M, Takeuchi M, Watanabe T, Yamamoto H. Nurture vs. nature in diabetic vasculopathy: roles of advanced glycation endproducts and the receptor for them. International Congress Series, Atherosclerosis XIII 2004; 1264: pp.164-7
  46. 糖尿病病態の分子生物学(門脇孝編)米倉秀人,渡邉琢夫,櫻井繁,山本靖彦,山本博「第10章 細小血管症の分子機構」pp.101-10 2004年 南山堂
  47. 老年医学 update2004-05 (日本老年医学会雑誌編集委員会) 山本靖彦,櫻井繁,渡邉琢夫,米倉秀人,山本博「AGE研究の最近の進歩」pp.25-33 2004年 メディカルレビュー社
  48. 血管 武内章彦,山本靖彦,櫻井繁,渡邉琢夫,米倉秀人,山本博「糖化蛋白による血管障害とその防止の分子機構」pp.125-30 2004年 日本脈管作動物質研究会
  49. Sakurai S, Yonekura H, Yamamoto Y, Watanabe T, Tanaka N, Li H, Rahman AK, Myint KM, Kim CH, Yamamoto H. The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 2003; 14:S259-63.
  50. Annual Review 2003 腎臓 大澤真里,山本靖彦,山本博「新しい糖尿病腎症モデル」pp.77-9 2003年 中外医学社
  51. 日本薬理学会雑誌 山本靖彦,櫻井繁,渡邉琢夫,米倉秀人,山本博「AGE-RAGE系を標的とした糖尿病血管障害抑制の可能性」pp.49-51 2003年 日本薬理学会
  52. 生化学 山本靖彦「AGE-RAGE系と糖尿病血管合併症」pp.1230-2 2003年 日本生化学会
  53. 生化学 渡邉琢夫,米倉秀人,山本靖彦,櫻井繁,山本博「糖尿病血管症の分子機構 (Molecular mechanism of diabetic angiopathy) -AGE-RAGE系を中心として-」pp.1361-70 2003年 日本生化学会
  54. 内科 山本靖彦,山本博 pp.1419-20「AGE-RAGE」2003年 南江堂
  55. 糖尿病学2002 山本靖彦,米倉秀人,渡邉琢夫,櫻井繁,土井俊夫,山本博「RAGEトランスジェニック糖尿病マウスにおける糖尿病腎症」pp.1-4 2002年 診断と治療社
  56. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Sakurai S, Yasui K, Petrova RG, Abedin Md.J, Li H, Rahman AK, Takasawa S, Okamoto H, Yamamoto H. The role of AGE-RAGE system in the development of diabetic nephropathy in vivo. Excerpta Medica International Congress Series 1245 (Horiuchi S, et al., eds) The Maillard Reaction in Food Chemistry and Medical Science: Update for The Postgenomic Era (7th International Symposium on the Maillard Reaction), ELSEVIER SCIENCE, Amsterdam, pp.45-50 2002
  57. ゲノムニュース(文部科学省科学研究費特定領域研究C「ゲノム」4領域広報委員会編)山本靖彦,米倉秀人,渡邉琢夫,山本博「Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice」No.1 pp.32-33 2002年
  58. Diabetes Frontier 渡邉琢夫,山本靖彦,櫻井繁,竹内正義,米倉秀人,山本博「高血糖による細胞内酸化ストレス増強機序1.終末糖化産物」pp.164-8 2002年 メディカルレビュー社
  59. Yonekura H, Yasui K, Sakurai S, Li H, Yamamoto Y, Yamamoto H. "Antisense display" - A new method for functional gene screen and its application to angiogenesis-related gene isolation. Ann NY Acad Sci 2001; 947:382-6.
  60. 分子糖尿病学の進歩(矢崎義雄監修,渥美義仁編)山本靖彦,米倉秀人,山本博「糖尿病合併症の発症とRAGE」pp.159-63 2001年 金原出版
  61. 日本糖尿病合併症 山本靖彦,加藤一郎,米倉秀人,大橋誠治,土井俊夫,田中伸茂,瀬川安則,櫻井繁,竹内正義,高澤伸,岡本宏,山本博「糖尿病血管合併症の分子標的」pp.106-9 2001年 日本糖尿病合併症学会
  62. 血管医学 特集:糖尿病性血管障害 櫻井繁,山本靖彦,安井潔,渡邉琢夫,米倉秀人,山本博「AGE受容体シグナリングと血管壁細胞障害」pp.33-8 2001年 メディカルレビュー社
  63. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, Takasawa S, Okamoto H, Abedin MdJ, Tanaka N, Sakurai S, Migita H, Unoki H, Wang H, Zenda T, Wu PS, Segawa Y, Higashide T, Kawasaki K, Yamamoto H. Roles of the AGE-RAGE system in vascular injury in diabetes. Ann NY Acad Sci 2000; 902:163-72.
  64. 実験医学 血管研究の最前線2000増刊号 山本靖彦,米倉秀人,Md. Joynal Abedin,田中伸茂,善田貴裕,卯木浩之,山岸昌一,山本博「糖尿病の血管障害」pp.107-10 2000年 羊土社
  65. 日本糖尿病合併症 山本靖彦,加藤一郎,土井俊夫,山岸昌一,米倉秀人,大橋誠治,高澤伸,岡本宏,竹内正義,山本博「AGEレセプター過剰発現糖尿病マウスにおける糖尿病性腎症の増悪」pp.10-3 2000年 日本糖尿病合併症学会
  66. Mebio別冊 Multiple risk factorと動脈硬化 山岸昌一,米倉秀人,山本靖彦,山本博「糖尿病と網膜血管障害」pp.261-6 1999年 メディカルビュー社
  67. 現代医療 山本靖彦,山岸昌一,米倉秀人,山本博 「糖尿病-AGE受容体」pp.144-7 1998年 現代医療社
  68. 実験医学増刊 血管の分子医学-その最前線 山岸昌一,米倉秀人,山本靖彦,山本博「糖尿病性網膜症の血管生物学」pp.188-91 1998年 羊土社
  69. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Yamamoto H. AGE and Endothelial Cell. J Atheroscler Thromb 1998; 4:141-3.
  70. 内分泌・糖尿病科 田中伸茂,米倉秀人,山本靖彦,山岸昌一,山本博「AGE-RAGE系制御による糖尿病合併症防止の可能性について」pp.188-91 1998年 科学評論社
  71. 分子糖尿病学 山本靖彦,山岸昌一,原田真市,米倉秀人,山本博「糖尿病−膵癌合併の分子メカニズム」pp.251-5 1997年 分子糖尿病学研究会編 医学図書出版
  72. 分子糖尿病学 山岸昌一,米倉秀人,山本靖彦,山本博「Advanced glycation endproductsの血管新生活性について」pp.243-9 1997年 分子糖尿病学研究会編 医学図書出版
  73. COMPLICATION−糖尿病と血管 山岸昌一,山本靖彦,米倉秀人,山本博「微小血管障害−血管新生−」pp.105-12 1996年 メディカルビュー社
  74. 口腔組織培養研究会誌 山本博,山岸昌一,野村素弘,林康彦,原田真市,徐成金,山本靖彦,川上卓久,劉暁旭,米倉秀人 「血管系細胞の"co-culture"と"hypoxic culture"」4(1) pp.1-7 1996年 口腔組織培養研究会
back top